Regular Hours
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| Valuation Estimation |
|
EPS (Current/Estimated)
5.94/6.58
|
|
Enterprise Value
58.79B
|
| Balance Sheet |
|
Book Value Per Share
12.25
|
| Cash Flow |
|
Cash Flow Yield
0.05
|
| Income Statement |
|
Total Revenue
9.26B
|
|
Operating Revenue Per Share
19.00
|
|
Industry Comparison
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
Quotes are at least 15-min delayed:2025/11/16 13:32 EST
Industry overview quotes are at least 15 minutes delayed
|
Business Description
|
|||
| Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companionanimal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit. |

120.82 
